These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 32457416)

  • 21. Nano-Systems for Advanced Therapeutics and Diagnosis of Atherosclerosis.
    Gaurav C; Saurav B; Goutam R; Goyal AK
    Curr Pharm Des; 2015; 21(30):4498-508. PubMed ID: 26377651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth factor therapy in atherosclerotic disease-friend or foe.
    Hoefer IE; Timmers L; Piek JJ
    Curr Pharm Des; 2007; 13(17):1803-10. PubMed ID: 17584109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid pharmacotherapy for treatment of atherosclerosis.
    Nicholls SJ; Pisaniello AD; Kataoka Y; Puri R
    Expert Opin Pharmacother; 2014 Jun; 15(8):1119-25. PubMed ID: 24702590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraplaque neovascularization as a novel therapeutic target in advanced atherosclerosis.
    Van der Veken B; De Meyer GR; Martinet W
    Expert Opin Ther Targets; 2016 Oct; 20(10):1247-57. PubMed ID: 27148888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk.
    Shapiro MD; Fazio S
    Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis.
    Alaarg A; Senders ML; Varela-Moreira A; Pérez-Medina C; Zhao Y; Tang J; Fay F; Reiner T; Fayad ZA; Hennink WE; Metselaar JM; Mulder WJM; Storm G
    J Control Release; 2017 Sep; 262():47-57. PubMed ID: 28700897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanomedicine to advance the treatment of bacteria-induced acute lung injury.
    Su R; Zhang Y; Zhang J; Wang H; Luo Y; Chan HF; Tao Y; Chen Z; Li M
    J Mater Chem B; 2021 Nov; 9(44):9100-9115. PubMed ID: 34672317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Goal of Achieving Atherosclerotic Plaque Regression with Lipid-Lowering Therapy: Insights from IVUS Trials.
    Daida H; Dohi T; Fukushima Y; Ohmura H; Miyauchi K
    J Atheroscler Thromb; 2019 Jul; 26(7):592-600. PubMed ID: 31118346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology (ESC) Working Group on atherosclerosis and vascular biology.
    Ylä-Herttuala S; Bentzon JF; Daemen M; Falk E; Garcia-Garcia HM; Herrmann J; Hoefer I; Jukema JW; Krams R; Kwak BR; Marx N; Naruszewicz M; Newby A; Pasterkamp G; Serruys PW; Waltenberger J; Weber C; Tokgözoglu L
    Thromb Haemost; 2011 Jul; 106(1):1-19. PubMed ID: 21670845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atherosclerosis, Periodontal Disease, and Treatment with Resolvins.
    Hamilton JA; Hasturk H; Kantarci A; Serhan CN; Van Dyke T
    Curr Atheroscler Rep; 2017 Nov; 19(12):57. PubMed ID: 29110146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management.
    Zhou Y; Xu M; Shen W; Xu Y; Shao A; Xu P; Yao K; Han H; Ye J
    Adv Healthc Mater; 2024 Jul; 13(17):e2304626. PubMed ID: 38406994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nano-sponge-like liposomes remove cholesterol crystals for antiatherosclerosis.
    Gong F; Wang Z; Mo R; Wang Y; Su J; Li X; Omonova CTQ; Khamis AM; Zhang Q; Dong M; Su Z
    J Control Release; 2022 Sep; 349():940-953. PubMed ID: 35870569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effective atherosclerotic plaque inflammation inhibition with targeted drug delivery by hyaluronan conjugated atorvastatin nanoparticles.
    Hossaini Nasr S; Rashidijahanabad Z; Ramadan S; Kauffman N; Parameswaran N; Zinn KR; Qian C; Arora R; Agnew D; Huang X
    Nanoscale; 2020 May; 12(17):9541-9556. PubMed ID: 32314997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of anti-atherosclerosis therapy based on the inflammatory and proliferative aspects of the disease.
    Maranhão RC; Leite AC
    Curr Pharm Des; 2015; 21(9):1196-204. PubMed ID: 25312729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet membrane-coated nanoparticle-mediated targeting delivery of Rapamycin blocks atherosclerotic plaque development and stabilizes plaque in apolipoprotein E-deficient (ApoE
    Song Y; Huang Z; Liu X; Pang Z; Chen J; Yang H; Zhang N; Cao Z; Liu M; Cao J; Li C; Yang X; Gong H; Qian J; Ge J
    Nanomedicine; 2019 Jan; 15(1):13-24. PubMed ID: 30171903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis.
    Caruthers SD; Cyrus T; Winter PM; Wickline SA; Lanza GM
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2009; 1(3):311-23. PubMed ID: 20049799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proprotein convertase furin/PCSK3 and atherosclerosis: New insights and potential therapeutic targets.
    Ren K; Jiang T; Zheng XL; Zhao GJ
    Atherosclerosis; 2017 Jul; 262():163-170. PubMed ID: 28400053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanomaterials to Resolve Atherosclerosis.
    Peters EB; Kibbe MR
    ACS Biomater Sci Eng; 2020 Jul; 6(7):3693-3712. PubMed ID: 33463318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanoparticle-mediated drug delivery system for atherosclerotic cardiovascular disease.
    Matoba T; Koga JI; Nakano K; Egashira K; Tsutsui H
    J Cardiol; 2017 Sep; 70(3):206-211. PubMed ID: 28416142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.